HOME > BUSINESS
BUSINESS
- Eisai’s Alzheimer’s Drug Leqembi Now Approved in Europe
April 16, 2025
- Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
- Asahi Kasei on Hunt for M&A and Licensing Deals to Bolster Pharma Biz
April 15, 2025
- Welcia, Tsuruha to Merge in December 2025 to Create Top Drugstore Group
April 15, 2025
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
- RaQualia Ends Tamibarotene License Pact with Syros
April 14, 2025
- Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
- Kaken Bags Japan Commercial Rights to KalVista’s HAE Drug
April 10, 2025
- KM Biologic President to Be Promoted to Meiji Group’s Pharma Chief
April 9, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
- JCR to Fuel Licensing of J-Brain Cargo, Invest in Global R&D: President
April 9, 2025
- Japan Infectious Disease Market Projected to Drop to 771.8 Billion Yen in 2033: Fuji Keizai
April 9, 2025
- Sanwa, Nissan Chemical to Jointly Develop Oligonucleotide for DRPLA in Japan
April 8, 2025
- Hong Kong Fund Oasis Sues Kobayashi Execs over Beni-Koji Scandal
April 8, 2025
- Japan Ethical Drug Sales Down 5.1% in February: Crecon
April 8, 2025
- Santen’s Glaucoma Drug Tapcom Snags China Approval
April 7, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Struggling Sumitomo Extends Pay Cuts for Board Directors
April 7, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer in Europe
April 7, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
